Klebanoff_Lab
@KlebanoffLab
Followers
3K
Following
17K
Media
20
Statuses
579
A translational research lab @MSKCancerCenter focused on the immunobiology and therapeutic potential of genetically engineered #Tcells and #TCRs. Est.2016 @NYC.
New York City, New York
Joined April 2021
🚨🧬💉Everything you wanted to know about TCR therapies* (*but were afraid to ask). Check out our new review in @NatRevDrugDisc 👇. A wonderful collaboration between @KlebanoffLab, @ND_BakerLab, @QuezadaLab, and @ToniRibas12. @MSKCancerCenter @parkerici
9
150
532
Very sad to hear about the passing of Dr. Zelig Eshhar, a maverick scientist who invented a class of chimeric immune receptors that combine antibody specificity with T-cell effector function. Originally called “T-bodies”, Zelig’s discovery would enable the field of CAR therapies.
We, the Weizmann Institute of Science community, deeply mourn the passing of Prof. Zelig Eshhar of the Department of Immunology and Regenerative Biology. Prof. Eshhar was a trailblazing scientist in the field of cancer immunotherapy, a recipient of the Israel Prize in Life
4
5
38
RT @CellCellPress: In the latest issue! Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias https://t.co/….
0
6
0
So excited to join my esteemed colleague @BernardAFox and an all star cast of speakers at the 40th @sitcancer Annual Meeting to discuss the therapeutic targeting of epitopes resulting from the #darkmatter of the cancer cell genome. Join us this November! #Tcellpower.
#SITC25 Science Preview: Join @BernardAFox @ChilesResearch, Christopher A. Klebanoff, MD @MSKCancerCenter, Rom S. Leidner, MD @ChilesResearch, Catherine Wu, MD @DanaFarber to describe novel cancer antigens derived from the dark genome. Browse details:
2
3
23
🙌🎉🍾Celebrating Fei and his recently accepted paper in @NatureCancer! Grateful to all of our collaborators, co-authors, and excellent peer reviewers @NathanSinghLab, #SaarGill, and @JoshuaBrodyMD. Stay tuned for the final manuscript! @MSKCancerCenter #Tcellpower #NKcellpower
2
4
74
🚨The *second* randomized clinical study to demonstrate significant survival benefit of T cell therapy Vs. standard of care for a relapsed/refractory solid cancer. Here, GEJ/gastric cancer using claudin 18.2 CAR-T. #Tecllpower.
1
16
66
RT @parkerici: Tomorrow at #ASCO2025, PICI CEO @DrKarenKnudsen takes center stage to receive ASCO’s Allen S. Lichter Visionary Leader Award….
0
5
0
RT @MSKCancerCenter: In a new study published in @CellPressNews, researchers from MSK and @fredhutch show that it may be possible to develo….
0
19
0
RT @PatrickHwuMD: #FollowFriday Chris Klebanoff is a talented medical oncologist and translational researcher @MSKCancerCenter, who is a le….
0
1
0
Bravo Eric 🧬🙌!.
Congratulations to Eric Smith, MD, PhD, @DanaFarber on receiving the Outstanding New Investigator Award from @ASGCTherapy. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025
1
0
6
Encounter with the legendary Tak Mak at the @EACRnews IO meeting in Barcelona 🇪🇸. Among many scientific discoveries, Tak co-discovered the #TCR and defined the function of #CTLA4. He’s also a super fun (and funny) dude. @sitcancer @MSKCancerCenter @parkerici #Tcellpower
2
3
63
RT @MSKCancerCenter: MSK physician-scientist @KlebanoffLab talked about all things #neoantigens for the Novel Classes of Human Cancer Rejec….
0
10
0
👉Today in @TheLancetOncol: phase I trial of #CISH KO #neoantigen-selected #TIL in GI cancers. Proud to have worked in collaboration with @cancerassassin1, the Webber/Moriarity labs @UMNCancer, and #IntimaBioscience from pre-clinical->IND->first-in-human.
4
2
29
🚨🧬Everything you wanted to know about actionable #neoantigens resulting from cancer mutations besides point mutations (*but were afraid to ask). Join us at 10:15 in 📍Room E351 - McCormick Lakeside Center (Level 3)! @MSKCancerCenter @UCSFCancer @institut_curie.
Join cellular therapist & early drug development specialist Dr. Christopher Klebanoff (@KlebanoffLab) for a symposium titled “Therapeutic targeting of public neoantigens resulting from recurrent gene fusions and mRNA mis-splicing events” today at #AACR25 (@AACR). Learn more:
1
3
32
Bravo @GormallyMDPHD 🙌🧬🥼!.
Happening now: MSK research fellow @GormallyMDPHD presents results from a real-world analysis evaluating HLA LOH frequencies and survival outcomes in #cancer at #AACR25.
0
0
4
RT @CancerResearch: Join Session Chair and CRI Investigator Dr. Klebanoff @MSKCancerCenter at 10:15 AM today for #AACR's SY16 - Novel Class….
0
2
0
RT @MSK_DeptOfMed: Research fellow @GormallyMDPHD will present results of a real-world analysis that evaluated HLA LOH frequencies & surviv….
0
5
0
🚨Today in @CellCellPress, we show that RNA splicing factor mutations in myeloid cancers generate splicing-derived public neoantigens targetable by #TCR tx. Amazing collaboration co-led by @AbdelWahablab, @bradleybio, and @KlebanoffLab. #Tcellpower .
10
32
141
Klebanoff Lab's "Physician-Scientist Action Hero." Mad scientist playset sold separately. *Batteries not included.
2
0
19
Cracking TP53! @GormallyMDPHD from @MSKCancerCenter presents on TCR gene therapy for undruggable TP53 hotspot mutations at #iwCART25. A new frontier in targeting solid tumors? 🧬🛠️ . #TP53 #TCRtherapy #ImmunoOncology
1
5
19
Excited to represent @sitcancer and join an amazing cadre of international IO investigators at @EACRnews 5th Immuno-Oncology Conference in Barcelona 🇪🇸. I'll be discussing emerging insights into the role of CD4+ T cells in anti-tumor immunity to human solid cancers. Join us!.
Join immunotherapy leaders from around the world at @EACRNews 5th Immuno-Oncology Conference in Barcelona! On May 15, view an expert presentation from @KlebanoffLab on “Therapeutic targeting of human cancers using CD4+ T cells”. Learn more:
0
0
16